Cancer Therapy : Preclinical Gene Expression Profiles Classify Human Osteosarcoma Xenografts According to Sensitivity to Doxorubicin , Cisplatin , and Ifosfamide

@inproceedings{Bruheim2009CancerT,
  title={Cancer Therapy : Preclinical Gene Expression Profiles Classify Human Osteosarcoma Xenografts According to Sensitivity to Doxorubicin , Cisplatin , and Ifosfamide},
  author={Skjalg Bruheim and Yaguang Xi and Jingfang Ju and Oystein Fodstad},
  year={2009}
}
Purpose: In osteosarcoma, aggressive preoperative and postoperative multidrug chemotherapy given to all patients has improved patient survival rate to the present level of ∼60%. However, no tumor marker is available that reliably can identify those patients who will or will not respond to chemotherapy. Experimental Design: In an attempt to find leads to such markers, we have obtained microarray gene expression profiles from a panel of 10 different human osteosarcoma xenografts and related the… CONTINUE READING

5 Figures & Tables

Connections & Topics

Mentioned Connections BETA
The expression data identified genes with highly significant differential expression between poor and good responder xenografts to the three different drugs : 85 genes for doxorubicin , 74 genes for cisplatin , and 118 genes for ifosfamide .
In an attempt to find leads to such markers , we have obtained microarray gene expression profiles from a panel of 10 different human osteosarcoma xenografts and related the results to their sensitivity to ifosfamide , doxorubicin , and cisplatin .
According to Sensitivity to Doxorubicin , Cisplatin , and Ifosfamide .
Current treatment regimens usually involve neoadjuvant and adjuvant chemotherapy with high - dose methotrexate , doxorubicin , cisplatin , and , more recently , ifosfamide .
Conclusions : The expression profiles contained several novel biomarker candidates that may help predict the responsiveness of osteosarcoma to doxorubicin , cisplatin , and ifosfamide .
In an attempt to find leads to such markers , we have obtained microarray gene expression profiles from a panel of 10 different human osteosarcoma xenografts and related the results to their sensitivity to ifosfamide , doxorubicin , and cisplatin .
According to Sensitivity to Doxorubicin , Cisplatin , and Ifosfamide .
Current treatment regimens usually involve neoadjuvant and adjuvant chemotherapy with high - dose methotrexate , doxorubicin , cisplatin , and , more recently , ifosfamide .
The expression data identified genes with highly significant differential expression between poor and good responder xenografts to the three different drugs : 85 genes for doxorubicin , 74 genes for cisplatin , and 118 genes for ifosfamide .
Conclusions : The expression profiles contained several novel biomarker candidates that may help predict the responsiveness of osteosarcoma to doxorubicin , cisplatin , and ifosfamide .
Current treatment regimens usually involve neoadjuvant and adjuvant chemotherapy with high - dose methotrexate , doxorubicin , cisplatin , and , more recently , ifosfamide .
Current treatment regimens usually involve neoadjuvant and adjuvant chemotherapy with high - dose methotrexate , doxorubicin , cisplatin , and , more recently , ifosfamide .
Current treatment regimens usually involve neoadjuvant and adjuvant chemotherapy with high - dose methotrexate , doxorubicin , cisplatin , and , more recently , ifosfamide .
Current treatment regimens usually involve neoadjuvant and adjuvant chemotherapy with high - dose methotrexate , doxorubicin , cisplatin , and , more recently , ifosfamide .
Current treatment regimens usually involve neoadjuvant and adjuvant chemotherapy with high - dose methotrexate , doxorubicin , cisplatin , and , more recently , ifosfamide .
Current treatment regimens usually involve neoadjuvant and adjuvant chemotherapy with high - dose methotrexate , doxorubicin , cisplatin , and , more recently , ifosfamide .
All Topics